KRW 253.2 billion revenue forecast lands for SK Biopharm stock

Published on 10/19/2026 at 03:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xcopri prescriptions rose 6.3 percent quarter over quarter in a Hana update on SK Biopharm stock. RISE2 targets a November restart after a partial clinical hold.

Clinical pipeline and earnings markers

Hana Securities forecast third-quarter revenue of KRW 253.2 billion on October 19, 2026.
Second-quarter revenue reached KRW 247.0 billion, up 40.3 percent year over year.
Market capitalization stood at KRW 5.8 trillion as of October 19, 2026.

SK Biopharm, KR7326030004, Illustration mit AI erstellt.

SK Biopharm (KR7326030004) is expected to post third-quarter revenue of KRW 253.2 billion, according to Seoul Economic Daily on October 19, 2026. Hana Securities also projected operating profit of KRW 96.8 billion, up 38.0 percent from a year earlier, as Xcopri prescriptions increased 6.3 percent from the previous quarter.

Forecast points to KRW 253.2 billion

The forecast puts third-quarter revenue 32.0 percent above the year-earlier period and operating profit 5.6 percent above consensus, with an estimated operating margin of 38.2 percent. The figures make prescription growth the immediate earnings driver, while the pipeline remains the larger strategic variable.

SK Biopharm's second-quarter revenue was KRW 247.0 billion, up 40.3 percent year over year, while operating profit reached KRW 97.1 billion, according to ATS View. The second-quarter operating margin was 39.2 percent, giving the company a high profitability base before the third-quarter milestone payment and higher development costs.

Three milestones and their figures

On September 16, 2026, Japan approved Xcopri, a decision tied to a milestone payment and future royalties, as Seoul Economic Daily reported. On October 16, 2026, the stock closed at KRW 73,300.00 on the Korea Exchange. On October 19, 2026, Hana Securities forecast third-quarter revenue of KRW 253.2 billion and operating profit of KRW 96.8 billion.

What does the hold mean for growth?

The partial U.S. clinical hold on opacalim is the main counterweight to the Xcopri-led earnings picture. RISE3 continues dosing after completing patient recruitment, while RISE2 has paused new enrollment; Biohaven is targeting a restart in November 2026, according to the Seoul Economic Daily report.

Next trial marker is November 2026

The next operational marker is the targeted November 2026 restart of RISE2. For investors, the key comparison is between the near-term earnings contribution from Xcopri and the timing risk attached to opacalim, which is being developed as a follow-on growth driver.

KRW 73,700.00 on the KRX

SK Biopharm was trading at KRW 73,700.00 on the Korea Exchange on October 19, 2026 at 10:32 a.m. KST during the open session. The quote sat within the 52-week range of KRW 67,800.00 to KRW 144,100.00, while market capitalization stood at KRW 5.8 trillion as of October 19, 2026.